Cargando…

Cystatin C is not a good candidate biomarker for HNF1A-MODY

Cystatin C is a marker of glomerular filtration rate (GFR). Its level is influenced, among the others, by CRP whose concentration is decreased in HNF1A-MODY. We hypothesized that cystatin C level might be altered in HNF1A-MODY. We aimed to evaluate cystatin C in HNF1A-MODY both as a diagnostic marke...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nowak, Natalia, Szopa, Magdalena, Thanabalasingham, Gaya, McDonald, Tim J., Colclough, Kevin, Skupien, Jan, James, Timothy J., Kiec-Wilk, Beata, Kozek, Elzbieta, Mlynarski, Wojciech, Hattersley, Andrew T., Owen, Katharine R., Malecki, Maciej T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2012
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898131/ https://www.ncbi.nlm.nih.gov/pubmed/22350134 http://dx.doi.org/10.1007/s00592-012-0378-1

Ejemplares similares

Circulating ghrelin level is higher in HNF1A–MODY and GCK–MODY than in polygenic forms of diabetes mellitus
por: Nowak, Natalia, et al.
Publicado: (2015)

Comparison of Glomerular Filtration Rate Estimation from Serum Creatinine and Cystatin C in HNF1A-MODY and Other Types of Diabetes
por: Szopa, Magdalena, et al.
Publicado: (2015)

Assessment of Newly Proposed Clinical Criteria to Identify HNF1A MODY in Patients with an Initial Diagnosis of Type 1 or Type 2 Diabetes Mellitus
por: Grzanka, Malgorzata, et al.
Publicado: (2016)

A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus
por: Hohendorff, J., et al.
Publicado: (2017)

High-Sensitivity CRP Discriminates HNF1A-MODY From Other Subtypes of Diabetes
por: McDonald, Tim J., et al.
Publicado: (2011)

Variants influencing age at diagnosis of HNF1A-MODY
por: Ludwig-Słomczyńska, Agnieszka H., et al.
Publicado: (2022)

Reduced penetrance of MODY-associated HNF1A/HNF4A variants but not GCK variants in clinically unselected cohorts
por: Mirshahi, Uyenlinh L, et al.
Publicado: (2022)

Differential regulation of serum microRNA expression by HNF1β and HNF1α transcription factors
por: Fendler, Wojciech, et al.
Publicado: (2016)

Association of birthweight and penetrance of diabetes in individuals with HNF4A-MODY: a cohort study
por: Locke, Jonathan M., et al.
Publicado: (2021)

A cross‐sectional study of patients referred for HNF1B‐MODY genetic testing due to cystic kidneys and diabetes
por: Sztromwasser, Paweł, et al.
Publicado: (2020)

Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level
por: Fendler, Wojciech, et al.
Publicado: (2014)

Response to Comment on: McDonald et al. High-Sensitivity CRP Discriminates HNF1A-MODY From Other Subtypes of Diabetes. Diabetes Care 2011;34:1860–1862
por: McDonald, Tim J., et al.
Publicado: (2011)

Syndromic monogenic diabetes genes should be tested in patients with a clinical suspicion of MODY
por: Colclough, Kevin, et al.
Publicado: (2022)

Double Heterozygous Mutations Involving Both HNF1A/MODY3 and HNF4A/MODY1 Genes: A case report
por: Forlani, Gabriele, et al.
Publicado: (2010)

A decision algorithm to identify patients with high probability of monogenic diabetes due to HNF1A mutations
por: Szopa, Magdalena, et al.
Publicado: (2019)

Qualitative Parameters of the Colonic Flora in Patients with HNF1A-MODY Are Different from Those Observed in Type 2 Diabetes Mellitus
por: Mrozinska, Sandra, et al.
Publicado: (2016)

Risk of macrosomia remains glucose-dependent in a cohort of women with pregestational type 1 diabetes and good glycemic control
por: Cyganek, Katarzyna, et al.
Publicado: (2016)

An Atypical HNF4A Mutation Which Does Not Conform to the Classic Presentation of HNF4A-MODY
por: Spiro, Andrew J., et al.
Publicado: (2018)

Circulating CD36 Is Reduced in HNF1A-MODY Carriers
por: Bacon, Siobhan, et al.
Publicado: (2013)

Efficacy of metformin versus sulfonylurea derivative in HNF4A-MODY
por: Oosterom, Nicole, et al.
Publicado: (2022)

Assessment of High-Sensitivity C-Reactive Protein Levels as Diagnostic Discriminator of Maturity-Onset Diabetes of the Young Due to HNF1A Mutations
por: Owen, Katharine R., et al.
Publicado: (2010)

Metabolic Profiling in Maturity-Onset Diabetes of the Young (MODY) and Young Onset Type 2 Diabetes Fails to Detect Robust Urinary Biomarkers
por: Gloyn, Anna L., et al.
Publicado: (2012)

Granuloma annulare and necrobiosis lipoidica in a patient with HNF1A-MODY
por: Brandes, Gabriela Irene Garcia, et al.
Publicado: (2022)

Genetic and Clinical Characterization of Patients with HNF1B-Related MODY in Croatia
por: Baretić, Maja, et al.
Publicado: (2023)

Two Cases of Diabetic Ketoacidosis in HNF1A-MODY Linked to Severe Dehydration: Is it time to change the diagnostic criteria for MODY?
por: Pruhova, Stepanka, et al.
Publicado: (2013)

Are late-night eating habits and sleep duration associated with glycemic control in adult type 1 diabetes patients treated with insulin pumps?
por: Matejko, Bartlomiej, et al.
Publicado: (2015)

Novel Use of GLP-1 Receptor Agonist Therapy in HNF4A-MODY
por: Broome, David T., et al.
Publicado: (2020)

Incidence of HNF1A and GCK MODY Variants in a South African Population
por: Matsha, Tandi E, et al.
Publicado: (2020)

MODY probability calculator for GCK and HNF1A screening in a multiethnic background population
por: Tarantino, Roberta Magalhães, et al.
Publicado: (2019)

Insights from basic adjunctive examinations of GCK‐MODY, HNF1A‐MODY, and type 2 diabetes: A systemic review and meta‐analysis
por: Liu, Jing, et al.
Publicado: (2023)

A multigenerational study on phenotypic consequences of the most common causal variant of HNF1A-MODY
por: Kettunen, Jarno L. T., et al.
Publicado: (2021)

HNF1B-MODY Masquerading as Type 1 Diabetes: A Pitfall in the Etiological Diagnosis of Diabetes
por: Francis, Youmna, et al.
Publicado: (2022)

Clinical Characteristics of Patients With HNF1-alpha MODY: A Literature Review and Retrospective Chart Review
por: Zhao, Qinying, et al.
Publicado: (2022)

South Asian individuals with diabetes who are referred for MODY testing in the UK have a lower mutation pick-up rate than white European people
por: Misra, Shivani, et al.
Publicado: (2016)

Development of an exoglycosidase plate-based assay for detecting α1-3,4 fucosylation biomarker in individuals with HNF1A-MODY
por: Demus, Daniel, et al.
Publicado: (2021)

Evaluation of Evidence for Pathogenicity Demonstrates That BLK, KLF11, and PAX4 Should Not Be Included in Diagnostic Testing for MODY
por: Laver, Thomas W., et al.
Publicado: (2022)

A Comprehensive Analysis of Hungarian MODY Patients—Part I: Gene Panel Sequencing Reveals Pathogenic Mutations in HNF1A, HNF1B, HNF4A, ABCC8 and INS Genes
por: Gaál, Zsolt, et al.
Publicado: (2021)

Diagnosis of hepatocellular adenoma in men before onset of diabetes in HNF1A‐MODY: Watch out for winkers
por: Haring, Martijn P. D., et al.
Publicado: (2019)

Using Clinical Indices to Distinguish MODY2 (GCK Mutation) and MODY3 (HNF1A Mutation) from Type 1 Diabetes in a Young Chinese Population
por: Fu, Junling, et al.
Publicado: (2019)

Interlaboratory evaluation of plasma N-glycan antennary fucosylation as a clinical biomarker for HNF1A-MODY using liquid chromatography methods
por: Demus, Daniel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jnuvp0doqct9k2ftpcotopg5s0